ClinicalTrials.gg
Status unknownNCT04466085Updated Dec 3, 2020

Clinical Study of Recombinant Novel Coronavirus Vaccine

A Phase 2 interventional study of Recombinant new coronavirus vaccine (CHO cell) low-dose group and Recombinant new coronavirus vaccine (CHO cells) high-dose group in Coronavirus, sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-03.

Sponsored by Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (part of Chongqing Zhifei Biological Products Co., Ltd.) · Phase 2, Interventional, and Prevention

The sponsor has not verified this record recently (last verified Dec 2020), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
900
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies in Coronavirus Infections with a site in China — 4 open to participants now, 6 under way, 3 of them phase 3. Coronavirus Infections · China.

Enrollment
8th of 24
900 · median 208
Started
2020
with 16 others
Phase 2
4 of 34
none open now
Registered
16th of 34
by date
Lead sponsor
5 of 34
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

Among the 34 studies in Coronavirus Infections with a site in China, this one is the 8th largest by enrollment of the 24 interventional ones that give a count, is one of 17 that started in 2020, is one of 4 in phase 2, and was the 16th registered.

Coronavirus Infections

1,112 studies on the registry are indexed under Coronavirus Infections; 52 are open to participants now.

Browse Coronavirus Infections studies →

Open to participants now

4 of the 34 studies in Coronavirus Infections with a site in China are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Coronavirus Infections studies recruiting now, 24 (60%) set no upper age limit and 9 (23%) stop at 75 or younger; 13 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 59 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Coronavirus Infections with a site in China, or all of them as a file.
02

Study summary

A total of 900 subjects are planned to be randomly divided into 2 doses of low-dose experimental vaccine group, 2 doses of high-dose experimental vaccine group, 2 doses of placebo group, 3 doses of low-dose experimental vaccine group, 3 doses of high-dose experimental vaccine group and 3 doses of placebo group, the sample size of each group was 150 cases.

Read the detailed description

A total of 900 subjects are planned to be randomly divided into 2 doses of low-dose experimental vaccine group, 2 doses of high-dose experimental vaccine group, 2 doses of placebo group, 3 doses of low-dose experimental vaccine group, 3 doses of high-dose experimental vaccine group and 3 doses of placebo group, the sample size of each group was 150 cases.

Subjects in the 2 dose group were injected with 2 doses of test vaccine or placebo in the upper arm deltoid muscle according to the 0,1 month immunization program, and subjects in the 3 dose group were injected with 3 doses of test vaccine or placebo in the upper arm deltoid muscle according to the 0, 1, 2 month immunization program .

03

Conditions studied

  • Coronavirus

Keywords

  • NOVID-19
04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Persons with full civil capacity aged 18-59 years (both included);
  • The subjects themselves voluntarily agreed to participate in the study, and signed an form, and can provide valid identification; understand and comply with the requirements of the trial protocol;
  • Body temperature under armpit \<37.3℃;
  • Female and male subjects of childbearing age agreed to take effective measures during the study.

Exclusion criteria

Exclusion Criteria:

  • The vital signs and physical examination results of the population specified in the plan have clinical significance as determined by the clinician;
  • A history of severe allergies to any component of the test vaccine, including aluminum preparations, such as: anaphylactic shock, allergic laryngeal edema, allergic purpura, thrombocytopenic purpura, local allergic necrosis (Arthus reaction), dyspnea, vascular neuropathy Edema, etc.; or any previous history of serious side effects after using any vaccine or drug;
  • Those with a history of SARS and SARS-CoV-2 (meet any of the following: ① previous history of SARS and SARS-CoV-2 infection or morbidity; ② during the current SARS-CoV-2 epidemic, there are patients diagnosed/suspected with the new crown Contact history);
  • Have taken antipyretics or painkillers within 24 hours before the first dose of vaccination;
  • Within 14 days before the first dose of vaccination, subunit vaccines, inactivated vaccines, and within 30 days;
  • People with the following diseases: Acute febrile disease; Digestive diseases (eg, diarrhea, abdominal pain, vomiting, etc.) in the past 7 days; Congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.; Congenital or Acquired immunodeficiency or a history of diseases or treatment with immunomodulators within 6 months, such as hormones; or monoclonal antibodies; or thymosin; or interferon, etc.; however, topical medications (such as ointment, eye drops, Inhalation or nasal spray); known to be diagnosed with infectious diseases, such as: patients with tuberculosis, viral hepatitis and/or HIV positive or syphilis specific antibody positive; neurological disease or Neurodevelopmental dysplasia (eg, migraine, epilepsy, stroke, seizures in the last three years, encephalopathy, focal neurological deficit, Guillain-Barré syndrome, encephalomyelitis or transverse myelitis); history of psychiatric illness or family History; functional spleenlessness, and spleenlessness or splenectomy for any reason; severe chronic disease or disease in progress that cannot be controlled smoothly, such as diabetes, thyroid disease; severe liver and kidney disease; respiratory tract that currently requires daily medication Diseases (eg, [COPD], asthma) or any treatment that exacerbates respiratory diseases (eg, asthma exacerbations) within the last 5 years; has severe cardiovascular disease (eg, congestive heart failure, cardiomyopathy, Ischemic heart disease, arrhythmia, conduction block, myocardial infarction, pulmonary heart disease) or a history of myocarditis or pericarditis; with thrombocytopenia, any coagulopathy, or treatment with anticoagulants; tumor patients;
  • Have received blood or blood-related products, including immunoglobulin, within 3 months; or plan to use it during the study;
  • Women who are breastfeeding or pregnant (including a positive urine pregnancy test);
  • Have used any research or unregistered product (medicine, vaccine, biological product or device) other than the research product within 3 months, or plan to use it during the research;
  • The researchers believe that any disease or condition in the subject may put the subject at an unacceptable risk; the subject cannot meet the protocol requirements; and interfere with the assessment of vaccine response.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
900 participants (actual)

Study arms

  • Experimental
    Population I

    In population I, there were 150 subjects who injected with 2 doses of low-dose test vaccine into the deltoid muscle of the upper arm according to the 0 and 1 month immunization schedule.

    Biological: Recombinant new coronavirus vaccine (CHO cell) low-dose group

  • Experimental
    Population II

    In population II, there were 150 subjects who injected with 2 doses of high-dose test vaccine in the upper arm deltoid muscle according to the 0 and 1 month immunization schedule.

    Biological: Recombinant new coronavirus vaccine (CHO cells) high-dose group

  • Placebo comparator
    Population Ⅲ

    In population Ⅲ, there were 150 subjects who injected with 2 doses of placebo in the upper arm deltoid muscle according to the 0 and 1 month immunization schedule.

    Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group

  • Experimental
    Population Ⅳ

    In population Ⅳ, there were 150 subjects who injected with 3 doses of low-dose test vaccine in the upper arm deltoid muscle according to the 0, 1, and 2 month immunization schedule.

    Biological: Recombinant new coronavirus vaccine (CHO cell) low-dose group

  • Experimental
    Population Ⅴ

    In population Ⅴ, there were 150 subjects who injected with 3 doses of high-dose test vaccine into the deltoid muscle of the upper arm according to the immunization schedule of 0, 1, and 2 months.

    Biological: Recombinant new coronavirus vaccine (CHO cells) high-dose group

  • Placebo comparator
    Population Ⅵ

    In Population Ⅵ, there were 150 subjects who injected with 3 doses of placebo into the deltoid muscle of the upper arm according to the immunization schedule of 0, 1, and 2 months.

    Biological: Recombinant new coronavirus vaccine (CHO cells) placebo group

Interventions

06

What researchers measure

Primary outcomes

  1. Neutralizing antibody positive conversion rate

    Neutralizing antibody positive conversion rate in the pre-immunization negative population 30 days after full vaccination

    Time frame: 30 days after inoculation

Secondary outcomes

  1. Neutralizing antibody GMT, positive rate

    GMT and positive rate of neutralizing antibody 14 days after the first dose of pre-vaccination people

    Time frame: 14 days after inoculation

  2. Neutralizing antibody GMT, positive conversion rate/positive rate

    GMT, positive conversion rate/positive rate of neutralizing antibodies 14 days after full vaccination in the pre-vaccination population

    Time frame: 14 days after inoculation

  3. Neutralizing antibody GMT

    Neutralizing antibody GMT 30 days after vaccination in pre-negative people

    Time frame: 30 days after inoculation

  4. Neutralizing antibody GMT

    Neutralizing antibody GMT in the 6th and 12th month after the entire vaccination

    Time frame: 6th and 12th month after inoculation

  5. Neutralizing antibody GMI, positive rate

    Neutralizing antibody GMI and positive rate at the 6th and 12th month of the entire vaccination

    Time frame: 6th and 12th month after inoculation

  6. IL-2, IL-4, IL-5, IL-6 and IFN-γ levels

    Levels of IL-2, IL-4, IL-5, IL-6 and IFN-γ on the 4th day and 12 months after the entire vaccination

    Time frame: 4th day and 12 months after inoculation

  7. Adverse events

    Adverse events 30 days after the first dose of vaccine to the entire exemption

    Time frame: 30 days after inoculation

  8. Serious adverse event

    Serious adverse events from day 0 after vaccination to 12 months after the entire immunization

    Time frame: 12 months after inoculation

07

Study locations

1 site
  • Hunan Provincial Center for Disease Control and Prevention
    Hunan, Changsha, China
08

References and documents

Publications

  • Yang S, Li Y, Dai L, Wang J, He P, Li C, Fang X, Wang C, Zhao X, Huang E, Wu C, Zhong Z, Wang F, Duan X, Tian S, Wu L, Liu Y, Luo Y, Chen Z, Li F, Li J, Yu X, Ren H, Liu L, Meng S, Yan J, Hu Z, Gao L, Gao GF. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24. PubMed 33773111 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Oct 2020, 3 months.

Of 38 industry-sponsored phase 2 interventional studies under Coronavirus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 14. This study's 3 months is below that.

Counting every sponsor, half of 107 studies reached it within 9 months; a quarter within 5 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2020
First posted
Jul 10, 2020
StartActual
Jul 12, 2020
Primary completionActual
Oct 22, 2020
CompletionEst.
Dec 15, 2021
Last update
Dec 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04466085
Responsible party
Sponsor
First posted
Jul 10, 2020
Start date
Jul 12, 2020
Primary completion
Oct 22, 2020
Completion
Dec 15, 2021 (estimated)
Last update
Dec 3, 2020

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CHO cell · CHO Cells

Start the discussion